Try our Advanced Search for more refined results

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. February 09, 2021

    Teva-Centric Price-Fix Case Likely To Lose Bellwether Status

    A Pennsylvania federal judge said Tuesday she was "no longer convinced" that a price-fixing lawsuit centered around Teva from state attorneys general should serve as a bellwether trial for multidistrict litigation accusing most of the generic-drug industry of price-fixing, thanks to related criminal charges against the company.

  2. January 03, 2021

    Antitrust Conduct Cases To Watch In 2021

    U.S. technology companies are facing a mountain of antitrust litigation heading into 2021, as enforcers push blockbuster monopolization cases against Google and Facebook. Meanwhile, long-running criminal probes in the generic drug and poultry industries are heating up. Here’s a look at the biggest antitrust conduct cases to watch.

  3. November 23, 2020

    Teva's Bid To Duck MDL Trials Slammed As 'Fool's Errand'

    A group of drug buyers and states asked a Pennsylvania federal judge Friday to reject Teva Pharmaceutical's bid to scrap a bellwether trial in multidistrict litigation over civil price-fixing claims to await the outcome of related criminal charges, calling the drugmaker's efforts to keep witnesses from overlapping a "fool's errand."

  4. September 10, 2020

    State AGs Say Drugmakers Want To Delay Price-Fixing Trials

    A contingent of state attorneys general suing generic-drug makers over allegations of price-fixing as part of a sprawling multidistrict litigation have said that drugmakers' proposed schedule for four bellwether cases would delay the first trial for months longer than necessary.

  5. August 27, 2020

    Pa. Avoiding Discovery In Price-Fixing Case, Drugmakers Say

    Generic-drug companies accused of orchestrating an industrywide price-fixing scheme have told a Pennsylvania federal court that the state attorney general's office is refusing to hand over documents they need to help mount a defense.

  6. August 12, 2020

    Resellers Say Drug Makers Erred In MDL Bellwether Claim

    A class of indirect resellers who are accusing a group of generic-drug makers of a price-fixing conspiracy in a multidistrict litigation case told a Pennsylvania federal court the drugmakers incorrectly reviewed the record before accusing the resellers of trying to avoid being among the first cases to go to trial.

  7. August 11, 2020

    Drugmakers Say Resellers Trying To Duck Bellwether Status

    A class of indirect resellers accusing a group of generic-drug makers of a price-fixing conspiracy don't want their cases to proceed to trial first in multidistrict litigation, the drugmakers told a Pennsylvania federal court in a Monday filing.

  8. July 14, 2020

    States' Case To Be Bellwether In Generic Drug Price-Fix MDL

    The Pennsylvania federal judge overseeing multidistrict litigation for price-fixing allegations in the generic drug industry has selected a case from state attorneys general to serve as a bellwether along with three private cases centered on individual drugs.

  9. June 10, 2020

    AGs Pile On Generics Cos. With 3rd Price-Fixing Complaint

    State enforcers added more treatments to their price-fixing case against generic-drug makers with a third complaint Wednesday in Connecticut federal court accusing 26 companies and 10 individuals of "rampant" collusion on topically applied treatments.

  10. April 03, 2020

    States' Suit Touted For Bellwether In Generics Price-Fix Case

    Buyers accusing generic-drug makers of price-fixing urged a Pennsylvania federal judge Thursday to accept a special master's recommendation and pick a lawsuit by states as their bellwether conspiracy case, pushing back against Teva Pharmaceuticals' objection to the special master's choice.